Page 23 - 2021_05-Haematologica-web

T-cell dysfunction in CLL
TOX and TOX2 transcription factors coop- erate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc Natl Acad Sci U S A. 2019;116(25):12410-12415.
61. Utzschneider DT, Kallies A. Human effector T cells express TOX—Not so “TOX”ic after all. Sci Immunol. 2020;5(49):eabc8272.
62. Sekine T, Perez-Potti A, Nguyen S, et al. TOX is expressed by exhausted and poly- functional human effector memory CD8+ T cells. Sci Immunol. 2020;5(49):eaba7918.
63. Aune TM, Collins PL, Chang S. Epigenetics and T helper 1 differentiation. Immunology. 2009;126(3):299-305.
64. Istaces N, Splittgerber M, Lima Silva V, et al. EOMES interacts with RUNX3 and BRG1 to promote innate memory cell formation through epigenetic reprogramming. Nat Commun. 2019;10(1):3306.
65. Sen DR, Kaminski J, Barnitz RA, et al. The epigenetic landscape of T cell exhaustion. Science. 2016;354(6316):1165-1169.
76. Kiaii S, Kokhaei P, Mozaffari F, et al. T cells from indolent CLL patients prevent apopto- sis of leukemic B cells in vitro and have altered gene expression profile. Cancer Immunol Immunother. 2013;62(1):51-63.
77. Roessner PM, Cid LL, Lupar E, et al. EOMES and IL-10 regulate anti-tumor activity of PD- 1+ CD4+ T-cells in B-cell non-Hodgkin lym- phoma. bioRxiv. 2020;2020.03.09.983098.
78.Solman IG, Blum LK, Hoh HY, et al. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020;97:106432.
79. Schmidl C, Delacher M, Huehn J, Feuerer M. Epigenetic mechanisms regulating T-cell responses. J Allergy Clin Immunol. 2018;142(3):728-743.
80. Janson PCJ, Linton LB, Bergman EA, et al. Profiling of CD4+ T cells with epigenetic immune lineage analysis. J Immunol. 2011;186(1):92-102.
81. Shih H-Y, Sciumè G, Poholek AC, et al. Transcriptional and epigenetic networks that drive helper T cell identities. Immunol Rev. 2014;261(1):23-49.
82. Wei G, Wei L, Zhu J, et al. Global mapping of H3K4me3 and H3K27me3 reveals speci- ficity and plasticity in lineage fate determi- nation of differentiating CD4+ T cells. Immunity. 2009;30(1):155-167.
83. Youngblood B, Oestreich KJ, Ha S-J, et al. Chronic virus infection enforces demethyla- tion of the locus that encodes PD-1 in anti- gen-specific CD8(+) T cells. Immunity. 2011;35(3):400-412.
84. Boer K, de Wit LEA, Peters FS, et al. Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation. Clin Epigenetics. 2016;8:116.
85. Zebley CC, Gottschalk S, Youngblood B. Rewriting history: epigenetic reprogram- ming of CD8+ T cell differentiation to enhance immunotherapy. Trends Immunol. 2020;41(8):665-675.
86. Haws SA, Leech CM, Denu JM. Metabolism and the epigenome: a dynamic relationship. Trends Biochem Sci. 2020;45(9):731-747.
87. Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microen- vironment for cancer immunotherapy. Mol Cell. 2020;78(6):1019-1033.
88. Zhong L, D’Urso A, Toiber D, et al. The his- tone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell. 2010;140(2):280-293.
89. Finlay DK, Rosenzweig E, Sinclair LV, et al. PDK1 regulation of mTOR and hypoxia- inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med. 2012;209(13):2441-2453.
90. Siska PJ, van der Windt GJW, Kishton RJ, et al. Suppression of Glut1 and glucose metab- olism by decreased Akt/mTORC1 signaling drives T cell impairment in B cell leukemia. J Immunol. 2016;197(6):2532-2540. Scharping NE, Menk AV, Moreci RS, et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intra-
tumoral T cell metabolic insufficiency and
dysfunction. Immunity. 2016;45(2):374-388. 92. Siska PJ, Rathmell JC. T cell metabolic fit- ness in antitumor immunity. Trends
Immunol. 2015;36(4):257-264.
93. Krämer AI, Handschin C. How Epigenetic
modifications drive the expression and mediate the action of PGC-1α in the regula- tion of metabolism. Int J Mol Sci. 2019;20(21):5449.
94. Bengsch B, Johnson AL, Kurachi M, et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory recep- tor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity. 2016;45(2):358-373.
95. Scharping NE, Rivadeneira DB, Menk AV, et al. Mitochondrial stress induced by continu- ous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021;22(2):205-215.
96. Dan Lu, Liu L, Sun Y, et al. The phosphatase PAC1 acts as a T cell suppressor and attenu- ates host antitumor immunity. Nat Immunol. 2020;21(3):287-297.
97. Galicia-Vázquez G, Aloyz R. Metabolic rewiring beyond Warburg in chronic lym- phocytic leukemia: how much do we actu- ally know? Crit Rev Oncol Hematol. 2019;134:65-70.
98.Serra S, Vaisitti T, Audrito V, et al. Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Adv. 2016;1(1):47-61.
99.Serra S, Horenstein AL, Vaisitti T, et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood. 2011;118(23):6141-6152.
100. Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20(9):516-531.
101. Arruga F, Serra S, Vitale N, et al. Targeting of the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia. Haematologica. 2021;106(5):1343-1353.
102. Mansouri L, Wierzbinska JA, Plass C, Rosenquist R. Epigenetic deregulation in chronic lymphocytic leukemia: clinical and biological impact. Semin Cancer Biol. 2018;51:1-11.
103. Jabbari P, Rezaei N. Artificial intelligence and immunotherapy. Exp Rev Clin Immunol. 2019;15(7):689-691.
104. Nieto P, Elosua-Bayes M, Trincado JL, et al. A single-cell tumor immune atlas for precision oncology. bioRxiv.;2020.10.26.354829.
105. Hartmann FJ, Mrdjen D, McCaffrey E, et al. Single-cell metabolic profiling of human cytotoxic T cells. Nat Biotechnol. 2021;30 (2):186-197.
106. Soshnev AA, Josefowicz SZ, Allis CD. Greater than the sum of parts: complexity of the dynamic epigenome. Mol Cell. 2016;62(5):681-694.
107. Bonev B, Cavalli G. Organization and func- tion of the 3D genome. Nat Rev Genet. 2016;17(11):661-678.
66. Beltra J-C, Manne S, Abdel-Hakeem MS, et al. Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020;52(5):825-841.e8.
67. Kavazović I, Han H, Balzaretti G, et al. Eomes broadens the scope of CD8 T-cell memory by inhibiting apoptosis in cells of low affinity. PLoS Biol. 2020;18(3):e3000648.
68.LiJ,HeY,HaoJ,NiL,DongC.Highlevels of Eomes promote exhaustion of anti-tumor CD8+ T cells. Front Immunol. 2018;9:2981.
69. Llaó Cid L, Hanna BS, Iskar M, et al. CD8+ T-cells of CLL-bearing mice acquire a tran- scriptional program of T-cell activation and exhaustion. Leuk Lymphoma. 2020;61(2): 351-356.
70. Park J, Kwon M, Kim KH, et al. Immune Checkpoint inhibitor-induced reinvigoration of tumor-infiltrating CD8+ T cells is deter- mined by their differentiation status in glioblastoma. Clin Cancer Res. 2019;25(8):2549-2559.
71. Hofland T, Martens AWJ, van Bruggen JAC, et al. Human CXCR5+PD-1+ CD8 T cells in healthy individuals and patients with hema- tologic malignancies. Eur J Immunol. 2021;51(3):703-713.
72. Bresin A, D’Abundo L, Narducci MG, et al. TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia. Cell Death Dis. 2016;7(1):e2071.
73.Hofbauer JP, Heyder C, Denk U, et al. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homolo- gous to human CLL. Leukemia. 2011;25(9):1452-1458.
74.Yigit B, Wang N, Hacken E ten, et al. SLAMF6 as a regulator of exhausted CD8+ T cells in cancer. Cancer Immunol Res. 2019;7(9):1485-1496.
75. Huang R, Li X, He Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86.
91.
haematologica | 2021; 106(5)
1243